Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities

Area of Science:

• Biochemistry
• Pharmacology
• Drug Design

Background:

• Mitochondrial carbonic anhydrase (CA) isoforms VA/VB are crucial for metabolic processes like lipogenesis and fatty acid synthesis.
• Clinical observations show that carbonic anhydrase inhibitors (CAIs) such as topiramate, zonisamide, and acetazolamide induce significant weight loss.
• This suggests potential therapeutic applications for CA VA/VB-selective inhibitors in obesity management.

Purpose of the Study:

• To review the current drug design landscape for developing selective and effective inhibitors of mitochondrial CA VA/VB.
• To explore various strategies employed in identifying and designing novel CA VA/VB inhibitors.
• To assess the potential of these inhibitors as antiobesity agents.

Main Methods:

• Review of existing literature on drug design approaches for CA inhibitors.
• Analysis of drug repurposing strategies for known CAIs.
• Examination of library screening (classical and virtual) and de novo drug design methodologies.
• Investigation of lead compounds including non-sulphonamide classes and classical sulphonamide derivatives.

Main Results:

• Multiple drug design approaches have been utilized, including repurposing, library screening, and de novo design.
• Lead compounds identified include diverse chemical classes beyond traditional sulphonamides, such as tropolones, phenols, and flavones.
• Classical drug design has yielded potent low nanomolar mitochondrial CA-selective sulphonamide inhibitors, though antiobesity studies are often limited.
• Hybrid molecules combining CAIs with other antiobesity agents represent a promising future direction.

Conclusions:

• The development of selective mitochondrial CA VA/VB inhibitors is an active area of drug design research.
• Various chemical scaffolds have shown promise, but understanding binding modes and conducting thorough antiobesity evaluations are critical.
• Hybrid drug design incorporating CAIs offers a potential breakthrough for effective obesity therapeutics.